Related references
Note: Only part of the references are listed.AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Garrett W. Rhyasen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP
Liangliang Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Thioredoxin-interacting protein, hematopoietic stem cells, and hematopoiesis
Haiyoung Jung et al.
CURRENT OPINION IN HEMATOLOGY (2014)
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Re-Place Your BETs: The Dynamics of Super Enhancers
Paulo P. Amaral et al.
MOLECULAR CELL (2014)
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
M. A. Dawson et al.
LEUKEMIA (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
TXNIP Maintains the Hematopoietic Cell Pool by Switching the Function of p53 under Oxidative Stress
Haiyoung Jung et al.
CELL METABOLISM (2013)
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Zhixiang Cheng et al.
CLINICAL CANCER RESEARCH (2013)
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
Anouk Emadali et al.
EMBO MOLECULAR MEDICINE (2013)
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
X. Zhao et al.
LEUKEMIA (2013)
A potential mechanism of metformin-mediated regulation of glucose homeostasis: Inhibition of Thioredoxin-interacting protein (Txnip) gene expression
Tin Fan Chai et al.
CELLULAR SIGNALLING (2012)
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia (AML)
Harald Herrmann et al.
ONCOTARGET (2012)
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
Jianbiao Zhou et al.
BLOOD (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms
Jianbiao Zhou et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Rongbin Zhou et al.
NATURE IMMUNOLOGY (2010)
Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway
Chia-Ling Chen et al.
BLOOD (2008)
Txnip balances metabolic and growth signaling via PTEN disulfide reduction
Simon T. Y. Hui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MYC - TIMELINE Reflecting on 25 years with MYC
Natalie Meyer et al.
NATURE REVIEWS CANCER (2008)
TXNIP regulates peripheral glucose metabolism in humans
Hemang Parikh et al.
PLOS MEDICINE (2007)
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function
E Junn et al.
JOURNAL OF IMMUNOLOGY (2000)